Zentalis Pharmaceuticals (ZNTL), set terms of its initial public offering, in which the biopharmaceutical company developing cancer treatments is expected to raise up to…
Zentalis is offering 7.65 million shares in the IPO, which is expected to price between $16 and $18 a share.
That would give the company a market capitalization of up to $591.7 million.
The stock is expected to list on the Nasdaq exchange under the ticker symbol “ZNTL.”
The lead underwriters are Morgan Stanley, Jefferies, SVB Leerink and Guggenheim Securities.
The company recorded a net loss of $45.7 million in 2019 on no revenue, after a loss of $21.1 million on $14,000 in revenue in 2018.
Zentalis is looking to go public at…
Continue reading at MARKETWATCH.com